| dc.description.abstract | Breast cancer is currently one of the most common malignancies in women. Fucoidan (FUC)
is a natural polysaccharide with anticancer properties. Despite a number of in vitro and in vivo
studies reporting the efficacy of fucoidan in treating various cancers, few studies have
measured the efficacy of fucoidan in combination with cancer drugs. Drugs like cisplatin,
doxorubicin and taxol are important in breast cancer treatment. However, in recent years,
supplements have gained importance in its treatment. Fucoidan, a sulfated polysaccharide
mainly found in brown algae and seaweed, is a new candidate for breast cancer therapy because
of its antitumour activity. This study was aimed at determining the cytotoxic, apoptotic and
cell cycle distribution effects of fucoidan and its synergistic and/or antagonistic effects in
combination with cisplatin, doxorubicin and taxol in the breast cancer cell line, MCF-7,
relative to the normal MCF-12A non-malignant breast epithelial cell line. | |
